BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cuppens T, Tuyaerts S, Amant F. Potential Therapeutic Targets in Uterine Sarcomas. Sarcoma 2015;2015:243298. [PMID: 26576131 DOI: 10.1155/2015/243298] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Abedin Y, Gabrilovich S, Alpert E, Rego E, Begum S, Zhao Q, Heller D, Einstein MH, Douglas NC. Gamma Secretase Inhibitors as Potential Therapeutic Targets for Notch Signaling in Uterine Leiomyosarcoma. IJMS 2022;23:5980. [DOI: 10.3390/ijms23115980] [Reference Citation Analysis]
2 Yoshida Y, Sasaoka S, Tanaka M, Matsumoto K, Inoue M, Satake R, Shimada K, Mukai R, Suzuki T, Iwata M, Goto F, Mori T, Mori K, Yoshimura T, Nakamura M. Analysis of drug-induced hand–foot syndrome using a spontaneous reporting system database. Therapeutic Advances in Drug Safety 2022;13:204209862211019. [DOI: 10.1177/20420986221101963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Strainienė S, Jauniškis K, Savlan I, Pamedys J, Stundienė I, Liakina V, Valantinas J. Paraneoplastic Phenomena of Disseminated Intravascular Coagulopathy in Hepatic Angiosarcoma – Rare, Challenging and Fatal. Case Report and Literature Review. AML 2021;28:1. [DOI: 10.15388/amed.2021.28.2.1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 De Wispelaere W, Annibali D, Tuyaerts S, Lambrechts D, Amant F. Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types? Cancers (Basel) 2021;13:2040. [PMID: 33922556 DOI: 10.3390/cancers13092040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Tavares M, Khandelwal G, Mutter J, Viiri K, Beltran M, Brosens JJ, Jenner RG. JAZF1-SUZ12 dysregulates PRC2 function and gene expression during cell differentiation.. [DOI: 10.1101/2021.04.15.440052] [Reference Citation Analysis]
6 Friedlander M, Benson C, O'Connell RL, Reed N, Clamp A, Lord R, Millan D, Nottley S, Amant F, Steer C, Anand A, Mileshkin L, Beale P, Banerjee S, Bradshaw N, Kelly C, Carty K, Divers L, Alexander L, Edmondson R. Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecol Oncol 2021;161:160-5. [PMID: 33608144 DOI: 10.1016/j.ygyno.2021.02.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Cabrera S, Bebia V, Acosta U, Franco-Camps S, Mañalich L, García-Jiménez A, Gil-Moreno A. Survival outcomes and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma. Clin Transl Oncol 2021;23:1210-9. [PMID: 33210235 DOI: 10.1007/s12094-020-02512-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
8 Zhang P, Zhang H, Wang Y. FGFR4 promotes nuclear localization of GABP to inhibit cell apoptosis in uterine leiomyosarcoma. Cell Tissue Res 2021;383:865-79. [PMID: 33151453 DOI: 10.1007/s00441-020-03296-5] [Reference Citation Analysis]
9 Lu YJ, Wang H, Fang LY, Wang WJ, Song W, Wang Y, Huang YQ, Din ZL. A nomogram for predicting overall survival in patients with uterine leiomyosarcoma: a SEER population-based study. Future Oncol 2020;16:573-84. [PMID: 32141309 DOI: 10.2217/fon-2019-0674] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
10 Atzori L, Pilloni L, Zanniello R, Ferreli C, Rongioletti F. Clear-cell variant of superficial cutaneous leiomyosarcoma associated with RB1 mutation: Clinical, dermoscopic, and histopathological characteristics. J Cutan Pathol 2020;47:571-5. [PMID: 31999365 DOI: 10.1111/cup.13655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Pradeep A, Sajitha K, Bhat S. Metachronous Sarcomas-a Case Report. Indian J Surg Oncol 2020;11:33-5. [PMID: 33088125 DOI: 10.1007/s13193-019-01005-5] [Reference Citation Analysis]
12 Mas A, Alonso R, Garrido-Gómez T, Escorcia P, Montero B, Jiménez-Almazán J, Martín J, Pellicer N, Monleón J, Simón C. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing. Am J Obstet Gynecol 2019;221:320.e1-320.e23. [PMID: 31121144 DOI: 10.1016/j.ajog.2019.05.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
13 Deng Y, Han Q, Mei S, Li H, Yang F, Wang J, Ge S, Jing X, Xu H, Zhang T. Cyclin-dependent kinase subunit 2 overexpression promotes tumor progression and predicts poor prognosis in uterine leiomyosarcoma. Oncol Lett 2019;18:2845-52. [PMID: 31452763 DOI: 10.3892/ol.2019.10668] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Sun S, Bonaffini PA, Nougaret S, Fournier L, Dohan A, Chong J, Smith J, Addley H, Reinhold C. How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagn Interv Imaging 2019;100:619-34. [PMID: 31427216 DOI: 10.1016/j.diii.2019.07.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
15 Rodríguez-Chávez JL, Méndez-Cuesta CA, Ramírez-Apan T, Egas V, Ávila JL, Neira-González A, Hernández T, Espinosa-García FJ, Delgado G. Chemo-sensitizing activity of natural cadinanes from Heterotheca inuloides in human uterine sarcoma cells and their in silico interaction with ABC transporters. Bioorg Chem 2019;91:103091. [PMID: 31319298 DOI: 10.1016/j.bioorg.2019.103091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
16 Xu Y, Liang ZX, Guo JT, Su X, Lu YL, Guan XZ. Cystic and solitary nodular pulmonary metastases in a patient with low-grade endometrial stromal sarcoma: A case report and literature review. Oncol Lett 2019;18:1133-44. [PMID: 31423173 DOI: 10.3892/ol.2019.10409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Sidorkiewicz I, Zbucka-Krętowska M, Zaręba K, Lubowicka E, Zajkowska M, Szmitkowski M, Gacuta E, Ławicki S. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers. BMC Cancer 2019;19:398. [PMID: 31035945 DOI: 10.1186/s12885-019-5558-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
18 Zang Y, Dong M, Zhang K, Gao C, Guo F, Wang Y, Xue F. Hormonal therapy in uterine sarcomas. Cancer Med 2019;8:1339-49. [PMID: 30897294 DOI: 10.1002/cam4.2044] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
19 Bobiński M, Okła K, Bednarek W, Wawruszak A, Dmoszyńska-Graniczka M, Garcia-Sanz P, Wertel I, Kotarski J. The Effect of Fucoidan, a Potential New, Natural, Anti-Neoplastic Agent on Uterine Sarcomas and Carcinosarcoma Cell Lines: ENITEC Collaborative Study. Arch Immunol Ther Exp (Warsz) 2019;67:125-31. [PMID: 30659312 DOI: 10.1007/s00005-019-00534-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
20 Teiken K, Kuehnel M, Rehkaemper J, Kreipe H, Laenger F, Hussein K, Jonigk D. Non-canonical WNT6/WNT10A signal factor expression in EBV+ post-transplant smooth muscle tumors. Clin Sarcoma Res 2018;8:10. [PMID: 29881541 DOI: 10.1186/s13569-018-0096-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
21 Kim MK, Lee TS, Kim JW, Lee JM, Kim BJ, Seong SJ. Management of Leimyosarcoma: A Survey Among Members of the Korean Gynecologic Oncology Group. Int J Gynecol Cancer 2017;27:1912-8. [PMID: 28930806 DOI: 10.1097/IGC.0000000000001104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
22 Hoang L, Chiang S, Lee C. Endometrial stromal sarcomas and related neoplasms: new developments and diagnostic considerations. Pathology 2018;50:162-77. [DOI: 10.1016/j.pathol.2017.11.086] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 13.6] [Reference Citation Analysis]
23 Korcsmaros T, Schneider MV, Superti-Furga G. Next generation of network medicine: interdisciplinary signaling approaches. Integr Biol (Camb) 2017;9:97-108. [PMID: 28106223 DOI: 10.1039/c6ib00215c] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
24 Horng HC, Wen KC, Wang PH, Chen YJ, Yen MS, Ng HT; Taiwan Association of Gynecology Systematic Review Group. Uterine sarcoma Part II-Uterine endometrial stromal sarcoma: The TAG systematic review. Taiwan J Obstet Gynecol. 2016;55:472-479. [PMID: 27590366 DOI: 10.1016/j.tjog.2016.04.034] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
25 Yen MS, Chen JR, Wang PH, Wen KC, Chen YJ, Ng HT; Taiwan Association of Gynecology Systematic Review Group. Uterine sarcoma part III-Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review. Taiwan J Obstet Gynecol 2016;55:625-34. [PMID: 27751406 DOI: 10.1016/j.tjog.2016.07.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
26 Cui RR, Wright JD, Hou JY. Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome. BJOG 2017;124:1028-37. [PMID: 28128524 DOI: 10.1111/1471-0528.14579] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
27 Ricci S, Stone RL, Fader AN. Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation. Gynecol Oncol. 2017;145:208-216. [PMID: 28209496 DOI: 10.1016/j.ygyno.2017.02.019] [Cited by in Crossref: 107] [Cited by in F6Publishing: 114] [Article Influence: 17.8] [Reference Citation Analysis]
28 Qiao Z, Tajima T, Kito F, Arai Y, Kawai A, Kondo T. Metastasis-associated gene signature in primary myxoid liposarcoma identified through a gene expression study. J Electrophor 2017;61:9-15. [DOI: 10.2198/jelectroph.61.9] [Reference Citation Analysis]
29 Wen K, Horng H, Wang P, Chen Y, Yen M, Ng H, Chang Y, Chang Y, Chao H, Chao K, Chuang C, Ho C, Huang C, Hung Z, Jiang L, Lau H, Li H, Lin C, Liu C, Sun P, Twu N, Wu H, Yu H, Ju F, Tsai C, Chang W, Hsu Y, Lee N, Chen C, Chang T, Chang W, Chen C, Chen R, Chow S, Lien Y, Sheu B, Torng P, Yen M, Lee W, Wang K, Chang C, Chen C, Chen J, Chen T, Huang J, Huang M, Wang Y, Chang C, Liu J, Su H, Wang Y, Yu M, Huang L, Seow K, Lai T, Lee F, Chen C, Huang B, Hsiao S, Sun H, Wu W, Teng S, Chen K, Hung J, Lai H, Yuan C, Hsieh C, Wang C, Chang S, Hung M, Hsu S, Ke Y, Lu C, Sun L, Chang W, Hung Y, Lin W, Wang P, Chen T, Li Y, Wu M, Huang K, Fu H, Chen S, Chiang A, Li J, Lin L, Tsai H, Tsui K. Uterine sarcoma Part I—Uterine leiomyosarcoma: The Topic Advisory Group systematic review. Taiwanese Journal of Obstetrics and Gynecology 2016;55:463-71. [DOI: 10.1016/j.tjog.2016.04.033] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]